This is CNBC’s coverage of how U.S. trade partners, industries and employers respond to President Donald Trump’s historic ...

We recently published a list of Jim Cramer’s Take on These 10 Stocks. In this article, we are going to take a look at where ...

Eli Lilly’s stock fell by 2.3% to close at 4:35 PM ET in after-hours trading, while Novo Nordisk’s American depositary receipts saw a decrease of 1.7%. This development came as a surprise to investors ...

Shares of Eli Lilly & Co. LLY shed 6.45% to $738.21 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 5.97% to 5,074.08 and Dow ...

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.

Shares of Eli Lilly & Co, the biggest Big Pharma stock by market capitalization, were not immune to Thursday’s rout caused by ...

Eli Lilly & Co. closed 18.86% short of its 52-week high of $972.53, which the company reached on August 22nd.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 ...

Altria has an impressive streak of raising its dividend for 55 consecutive years. Eli Lilly's current streak only goes back ...